Integrated Personalized Diabetes Management Goes Europe:

Did you know?

  • Diabetes affects approximately 58 million European citizens,1
  • In 2017, around 477.000 deaths were attributed to diabetes in Europe alone,1
  • In 2017 the estimated total healthcare costs for diabetes in Europe exceeded 160 billion US dollars,1
  • By 2045, it is estimated that 67 million people in Europe will have diabetes,1

iPDM-GO Mission

By delivering integrated personalised diabetes management (iPDM) our primary goal is to positively impact the lives of people living with type 2 diabetes. Through the development and delivery of personalized solutions and services we strive to support diabetes self-management and improve citizens’ quality of life. Furthermore, we believe that iPDM-GO can serve as a proof-of-concept for other chronic diseases, as we aim to realize outcomes-orientated healthcare in Europe.

What is iPDM-GO?



Integrated personalised diabetes management (iPDM) is a therapeutic approach that structures the diabetes treatment process, connects healthcare professionals and patients, and integrates digital tools that visualise and analyse data.2,3 As such, iPDM is a process that supports healthcare professionals and their patients in their joint decision making. The iPDM concept consists of six steps (Figure)

The iPDM-GO consortium will implement iPDM in a Danish community setting with the goal of laying the groundwork for expanding to additional European countries. This scaling process will be guided by an international multi-stakeholder advisory board and include a thorough health systems analysis.

In parallel, the iPDM-GO consortium will develop a novel patient-assessment tool to enhance iPDM and personalize treatment to the specific needs and requirements of the individual person with diabetes. The tool will be co-created in a user-centric design process that considers early input from relevant stakeholders. Additionally, iPDM-GO will use machine learning methodologies to explore new opportunities for leveraging Big Data resources. We will also develop effective educational programs for healthcare professionals to learn about the key factors of success when implementing iPDM.

Importantly, to contribute to the transformation of healthcare from volume-based to value-based, iPDM-GO will develop a healthcare transformation toolkit that supports the implementation of value-based healthcare in European countries based on the iPDM process.

Find out more about the concepts underlying iPDM and how they feed into iPDM-GO by checking out our new eLearning module here.

A Digital Transition – Our Three-Year Plan

With everyday life becoming increasingly digital, we aim to be at the forefront of the digital healthcare shift, bringing iPDM as a change maker to the diabetes landscape. In this respect, iPDM takes a modern digital approach to diabetes treatment that makes it easier for patients to communicate with their treating physicians

In the next three years iPDM-GO will:

  • Leverage the opportunities provided by true co-creation considering all stakeholders
  • Enable personalized and patient-centric diabetes care
  • Offer an opportunity to implement value-based healthcare
  • Empower patients to make better-informed choices built on their individual treatment needs and personal preferences
  • Help doctors make better-informed therapy choices based on the needs of the individual patient

Achievements to date

In total 25 members of the consortium met in Copenhagen for two days to informally get to know each other, align on workplans and discuss administrative tasks. Each work package leader presented a detailed plan for the current and future project periods.

January 2019: iPDM-GO consortium kick off meeting

iPDM-GO consortium member Professor Freimut Schliess published a blog post on the connections between digital diabetes management and EIT Health

February 2019: Blog post on Digital Health

The iPDM-GO medical education strategy will primarily focus on the interdisciplinary team of healthcare professionals and young professionals developing innovative technologies and services. Highlights of the plan include:

  • A design thinking workshop delivered in collaboration with the European Molecular Biology Laboratory (Year 2)
  • A satellite symposium at an international diabetes congress (Year 2 or 3)
  • A train the trainer program for the multidisciplinary team of HCPs (Year 3)

Our ambition is to ensure that these activities are not only of the highest quality, but also help raise awareness of the project, the involved partners and EIT Health itself.

June 2019: iPDM-GO educational strategy completed

Our Advisory Board consisting of ten experts in the field of diabetes, patient care and disease management met at the IDF Europe offices to discuss their involvement in the execution of iPDM-GO. One of the key takeaways of the initial meeting was to shortlist key markets in Europe and then develop a list of indicators to analyse the countries on a micro-level.


July 2019: First iPDM-GO Advisory Board meeting held in Brussels

Two iPDM-GO abstracts have been acceptedfor presentation at scientific conferences. Dr. Allan Jones will present the overall iPDM-GO project at the EMBO Workshop “Precision Health: Molecular Basis, Technology and Digital Health” in Heidelberg (November 13-16) while Dr. Laila Starr will present our health-economic approach at the upcoming “ISPOR Europe” congress in Copenhagen (November 2-6).


August 2019: iPDM-GO abstracts accepted

Dr. Allan Jones presented iPDM-GO to leadership members of approximately 35 EIT Health industry partners in Amsterdam. The project was presented under the heading “How can we innovate together with payers and healthcare providers to deliver cost-effective interventions that deliver better health outcomes for patients?”

September 2019: iPDM-GO presented at the EIT Health Industry Round table

Our iPDM-GO Advisory Board

The iPDM-GO multi-stakeholder Advisory Board comprises healthcare professionals, patients, private and public payers  as well as leading researchers in value-based healthcare and integrated care. The Advisory Board is coordinated by the International Diabetes Federation’s European chapter (IDF Europe). The group meets twice per year and provides input regarding the implementation of iPDM in a value-based healthcare setting.

Why is it an EIT Health project?

iPDM-GO is in keeping with the EIT Health Focus Area of “Care Pathways”, because it seeks to improve care, by making it more results-oriented. The project also aligns with the Focus Area of “Bringing Care Home”, because it encourages an approach that allows people with diabetes to do more to take care of themselves.


EIT Health Partners in this project

External Partners

  • Region Sjælland
  • City of Copenhagen (Københavns Kommune)

Key Publications to Date


Primary publications



Your main contact

Dr. Dagmar Kownatka

Roche Diabetes Care Deutschland GmbH


  1. International Diabetes Federation. IDF Diabetes Atlas, 8th edn. Brussels, Belgium:
    International Diabetes Federation, 2017.
  2. Heinemann L et al. Benefit of Digital Tools Used for Integrated Personalized Diabetes Management: Results From the PDM-ProValue Study Program. J Diabetes Sci Technol. (2019)
  3. Kulzer B et al. Integrated personalized diabetes management improves glycemic control in patients with insulin-treated type 2 diabetes: Results of the PDM-ProValue study program.Diabetes Res Clin Pract. (2018)